Ra­dio­phar­ma­ceu­ti­cal com­pa­ny Telix aims for $202M IPO

Amid boom­ing in­ter­est in ra­dio­phar­ma­ceu­ti­cals, Telix Phar­ma­ceu­ti­cals is plan­ning to be­come a pub­licly trad­ed com­pa­ny in the US.

The biotech, based in North Mel­bourne, Aus­tralia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER